Clinical Trial Update: Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding

View source ↗

Summary

A long-term safety study update for Jivi (emicizumab) in patients with Hemophilia A who are already receiving Jivi to prevent bleeds.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Jivi

Snippet

Sponsor: Bayer | Conditions: Hemophilia A | Status: ACTIVE_NOT_RECRUITING